Gastrointestinal Stromal Tumors

Conference Insider

Ripretinib Yields Clinical Benefit; Proven Tolerability in Advanced GIST

06/17/2021

INVICTUS study results reveal intra-patient dose escalation (IPDE) of ripretinib after disease progression indicate clinical benefit and tolerability in patients with advanced gastrointestinal stromal tumors.

INVICTUS study results reveal...

06/17/2021

Oncology

Conference Insider

Experts Investigate Value of Chromosomal Complexity in Imatinib Treatment for High-Risk GIST

06/17/2021

Investigators sought to determine if chromosomal complexity could be used as a biomarker in de-escalation of adjuvant imatinib treatment, presented at the 2021 ASCO Annual Meeting.

Investigators sought to...

06/17/2021

Oncology

Conference Insider

Pimitespib Significantly Improves PFS, OS in Patients with Advanced GIST

06/15/2021

A phase III trial evaluated the efficacy and safety of pimitesib in patients with advanced GIST refractory to standard treatments, whose medical requirements remain unmet, presented at the 2021 ASCO Annual Meeting.

A phase III trial evaluated the...

06/15/2021

Oncology

Conference Insider

Selinexor+Imatinib Combo Found Well Tolerated in IM-Resistant Advanced GIST

06/15/2021

Results following the phase Ib portion in the evaluation of imatinib in combination with selinexor displays well tolerability in patients with imatinib (IM)-resistant, advanced GIST, presented at the 2021 ASCO Annual Meeting.

Results following the phase Ib...

06/15/2021

Oncology